Introduction {#sec1-1}
============

Primary cutaneous apocrine carcinoma (PCAC) is a rare cutaneous malignancy with the incidence of 0.005--0.017 per 100,000 patients per year.\[[@ref1]\] Approximately 200 cases were reported in the literature and most of those cases were originated in areas with large numbers of apocrine glands as the axilla. Only a few cases were originated from the scalp.\[[@ref2][@ref3]\] These malignancies have an equal distribution between males and females, with the peak of presentation in the 6^th^ and 7^th^ decades of age and the predominance to Caucasian ethnicity.\[[@ref4]\] Due to the similarity of the morphological profile, it is difficult to differentiate from metastases breast adenocarcinoma. It is crucial to perform detailed clinical presentation and thorough examination to search of a primary site in such cases.\[[@ref5]\] Frequently, it infiltrated the epidermal layer resulting in ulceration. PCAC has a diverse presentation, occurring as both uninodular and multinodular growths with varying color.\[[@ref1][@ref2]\] Often these tumors are indurated, painless masses, and can be associated with benign lesions, as a nevus sebaceous and most commonly seen with scalp lesions.\[[@ref6]\] Development of these lesions typically occurs within a year before diagnosis.\[[@ref7]\] However, several cases have reported longer durations with a period of rapid growth.\[[@ref8]\] Of the 200 cases of PCAC, few cases have reported detailed accounts of scalp primaries.\[[@ref1]\] We report the case of a 56-year-old man who presented with scalp ulcerative lesion treated with wide local excision. Later, he developed neck lymph node metastasis treated with surgery and adjuvant radiation. We review reported cases in the literature on the clinical presentation, treatment, and outcomes of such rare tumors.

Methods {#sec1-2}
=======

Case report {#sec2-1}
-----------

A 56-year-old male patient presented to head and neck clinic with an ulcerative lesion in the right temporal area of the scalp since the last 3 years that gradually increased in size and associated with mild pain. He denied any history of other skin lesion or swelling in the neck. He has no history of smoking, alcohol consumption, or sun exposure. On physical examination, the lesion was an ulcerative measuring approximately 3 × 3 cm. There was no palpable cervical lymphadenopathy. No pre- or postauricular lymphadenopathy. No other suspicious skin lesions of the face or the neck were found. The rest of the examination was unremarkable. Head and neck computerized tomography (CT scan) did not show any evidence of pathologic lymph nodes or masses. Staging with CT scan of the chest, abdomen, and pelvis was also negative for metastatic disease. The patient underwent complete local excision and split-thickness skin graft. Histopathology assessment revealed skin tissue infiltrated by neoplastic growth composed of tubules, cords, and nests of malignant cells. The extensive perineural invasion was seen. There was no lymphovascular invasion. The resection margins were clear. The pathology confirmed an apocrine cutaneous carcinoma \[see [Figure 1](#F1){ref-type="fig"}\]. The case was reviewed in the head and neck tumor board and the decision of no adjuvant treatment. 1.5 years later, the patient presented to the combined head and neck oncology clinic with right neck lymphadenopathy for the last few weeks. On physical examination, there was around 2 × 2 cm mass in the right posterior neck looks like a lymph node. CT scan of the head and neck revealed 1.8 × 1.5 cm right neck lymph node at the level Va with central necrosis \[see [Figure 2](#F2){ref-type="fig"}\]. FNA biopsy was taken and histopathology reported malignant cells to consist with metastatic of cutaneous malignancy. The patient underwent right modified radical neck dissection and the histopathology reported the diagnosis of metastatic cutaneous apocrine carcinoma. The case again discussed in the tumor board and the plan was to give adjuvant radiation therapy. No chemotherapy was given. During his follow-up for the last few years, the patient was from the disease on the clinical and radiological evaluation.

![(a): Sheets of tumor cells composed of tubules, cords, and nests of malignant cells with high nuclear to cytoplasmic ratio and nuclear pleomorphism (H and E stain; magnification × 10); (b): Tumor cells invading skeletal muscles (H and E stain; magnification × 10); (c): Tumor cells extending deep into the fat and subcutaneous tissue (H and E stain; magnification × 4); (d): Extensive perineural invasion (H and E stain; magnification; ×4)](JFMPC-8-3758-g001){#F1}

![CT scan of the patient\'s neck revealed the right posterior triangle necrotic Lymph node measuring 1.8 × 1.5 cm](JFMPC-8-3758-g002){#F2}

Discussion Summary of the Literature Review {#sec1-3}
===========================================

We conducted a literature review through the PubMed engine to evaluate clinical presentation, the treatment options, and the prognosis for patients with PCAC of the scalp. Eighteen cases had detailed reports and were collected and summarized in [Table 1](#T1){ref-type="table"}.\[[@ref1]\] We added our case, so the total is 19 cases. Out of the 19 cases, 11 females (57.9%) and eight males (42.1%) made up the cohort. The mean age was 57 years with a range from 20 to 85 years of age. The size of the scalp lesions varied among the cohort, ranging from 0.5 to 7.5 cm, with an average of 3.1 cm. There were seven cases, all of, with an average size of 2.2 cm at presentation. The average size of the metastatic lesions was 5.9 cm that was higher than the average size of non-metastatic lesions which was 4 cm or less. 12/19 (63.2%) patients were presented with the only local cutaneous disease. 3/19 (15.8%) patients were presented with cervical lymphadenopathy at the time of diagnosis. Metastatic disease was not present at diagnosis in any of the reported cases. No details of disease presentation were reported in four patients. The scalp PCAC lesions exhibited variable growth patterns among the 10 cases that had reported these details ranging from slow progressive to rapid and aggressive presentation. The primary treatment was the surgical excision (local complete vs. wide or radical), occurring in 18/19 (94.7%) patients. Details of the primary treatment were demonstrated in [Table 2](#T2){ref-type="table"}. Details regarding disease progression, local versus regional recurrence, and distant metastases were summarized in [Table 3](#T3){ref-type="table"}. For local recurrences without the involvement of regional lymph nodes, wide excision of the tumor was the main treatment. In case of regional lymph node metastasis, neck dissection or radiation or both were the treatment in most of the cases. For the patients that had developed metastatic disease, combinations of chemotherapy and/or radiotherapy were the palliative treatment in most of the cases. Common sites of distant metastasis occurred in the distant lymph nodes as the axillary lymphadenopathy, the bones, the brain, and the lungs. From the time of metastatic diagnosis, survival ranged from approximately 1--4 years, with an average of 2.25 years.\[[@ref1][@ref2][@ref3][@ref9][@ref10][@ref11]\]

###### 

Clinical Data of 19 Case Reports of Primary Cutaneous Apocrine Carcinoma of the Scalp. (Editing of the table that was done by Brown ZM *et al.* 2016 after permission)\[[@ref1]\]

  Reference                              Age   Sex   Size (cm)   Time Evolved                                                                                 Lymph Node Status at Diagnosis   Primary Treatment                                                           Recurrence/Metastases and Treatment                                                                                                                                                                                     Outcome (Follow-up)
  -------------------------------------- ----- ----- ----------- -------------------------------------------------------------------------------------------- -------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Domingo and Helwig (1979)\[[@ref6]\]   77    M     2×1.2       \>17 y 1.5 m growth                                                                          NR                               Excision (margins not specified)                                            1\) LN Cervical (6 m) - ND 2) LR (1.5y) - Treatment NR                                                                                                                                                                  AWD (1.5 y)
  Domingo and Helwig (1979)\[[@ref6]\]   63    F     1.5         Birth                                                                                        NR                               Excision (margins not specified)                                            NED                                                                                                                                                                                                                     NED (6 y)
  Domingo and Helwig (1979)\[[@ref6]\]   68    F     0.7         Unknown                                                                                      NR                               Excision (margins not specified)                                            NR                                                                                                                                                                                                                      LTF
  Domingo and Helwig (1979)\[[@ref6]\]   65    M     7           Birth 1 m growth                                                                             NR                               Excision (margins not specified)                                            1\) LN Post-auricular, cervical and supraclavicular (6 m) - Treatment Radiotherapy 2) Distant Bone Mets. (9 m) - Treatment Radiotherapy                                                                                 DWD (2 y)
  Paties *et al.* (1993)\[[@ref9]\]      85    M     3.5         20 y                                                                                         NR                               Excision (margins not specified)                                            LN Cervical posterior (2y) - Treatment NR                                                                                                                                                                               DOC (2.5 y)
  Jacyk *et al.* (1998)\[[@ref12]\]      54    F     4×1         Since Childhood Few month growth                                                             No LN                            Excision (margins not specified)                                            NED                                                                                                                                                                                                                     NED (1 y)
  Morbabito *et al.* (2000)\[[@ref2]\]   46    F     NR          NR                                                                                           NR                               Excision (margins not determined)                                           1\) LR (temporal) and LN Cervical (4 m) - Radical excision and ND, Radiotherapy, Chemo; 2) Cutaneous Mets. & Cervical LN (13 m) - Chemotherapy (17 m); 3) Cutaneous Scalp Lesion Progression (26 m) - Treatment NR      DOC (28 m)
  Shimato *et al.* (2006)\[[@ref13]\]    48    M     5           NR                                                                                           Cervical LN                      Wide excision (2 cm free margins) and ND                                    1\) Lung Mets. (4y) - Chemotherapy; 2) Brain Mets. (6y) - Excision and Radiotherapy; 3) Brain recurrence (7y) - Excision; 4) Lung Mets. Progression (8y)                                                                DWD (8 y)
  Robson *et al.* (2008)\[[@ref14]\]     73    F     0.5         NR                                                                                           NR                               Complete Local Excision (margins not determined)                            NED                                                                                                                                                                                                                     LTF
  Robson *et al.* (2008)\[[@ref14]\]     63    F     2.4         NR                                                                                           NR                               Complete Local Excision (margins not determined)                            NR                                                                                                                                                                                                                      LTF
  Robson *et al.* (2008)\[[@ref14]\]     70    F     1.9         NR                                                                                           NR                               Complete Local Excision (margins not determined)                            NED                                                                                                                                                                                                                     NED (2.5 y)
  Robson *et al.* (2008)\[[@ref14]\]     43    F     7.5         6 m                                                                                          NR                               Complete Local Excision (margins not determined)                            Metastases (specific details of metastases and treatment not mentioned)                                                                                                                                                 DWD (6 y)
  Robson *et al.* (2008)\[[@ref14]\]     31    M     1.4         3 m                                                                                          NR                               Complete Local Excision (margins not determined)                            NR                                                                                                                                                                                                                      LTF
  Tlemcani *et al.* (2010)\[[@ref10]\]   20    M     NR          Several Weeks                                                                                NR                               Excision (margins not determined)                                           LR, LN, Bone and Lung Mets. (16 m) - Palliative Radiotherapy and Chemotherapy                                                                                                                                           DWD (55 m)
  Kim *et al.* (2011)\[[@ref15]\]        60    F     2×1.5       NR                                                                                           NR                               Chemotherapy                                                                LR (7y) - Wide excision (2 cm free margins)                                                                                                                                                                             NED (8 y)
  Paudel *et al.* (2012)\[[@ref11]\]     45    M     2×2         Since Childhood 4 m growth                                                                   Cervical LN                      Excision (margins not determined)                                           NR                                                                                                                                                                                                                      NR
  Vucinic *et al.* (2012)\[[@ref3]\]     65    F     4           NR (Prior history of scalp mass & enlarged neck LN 3 years prior) (Treatment not reported)   Cervical LN                      Radical Excision (2 cm free margins) and ND Chemotherapy and Radiotherapy   1\) LR and LN (contralateral cervical) (10 m) -Re-excision & ND; 2) LR and LN (Cervical & Axillary) (12 m) - Re-excision, ND & chemo; 3) LN, Bone, Cutaneous & Lung Mets. (16 m) -Bisphosphonate & Supportive Therapy   DWD (3 y)
  Brown ZM *et al.* (2016)\[[@ref1]\]    42    F     3×2         NR                                                                                           No LN                            Local Excision (clear margins minimum 2 mm)                                 NED                                                                                                                                                                                                                     NED (39 m)
  Al-Hakami HA *et al.* (2018)           56    M     3×3         3 y                                                                                          No LN                            Local Excision (clear not specified margins) and STSG                       LN (Cervical single right 1.8×1.5 cm) after 1.5 y - MRND & Radiotherapy                                                                                                                                                 NED (2 y)

LN - Lymph Node; LR - Local Recurrence; ND - Neck Dissection; AWD - Alive with Disease; NED - No Evidence of Disease; LTF - Lost to Follow-up; DWD - Died with Disease; DOC - Died of other causes; NR - Not reported; MRND- Modified Radical Neck Dissection; STSG - Split Thickness Skin Graft.

###### 

Type of primary treatment among 19 cases of PCAC of the scalp

  Primary Treatment        *n* (%) (*n*=19)
  ------------------------ ------------------
  Surgery                  **18 (94.7%)**
   Local Excision          16 (88.9%)
   Wide/Radical Excision   2 (11.1%)
  Radiotherapy             **1 (5.3%)**
  Chemotherapy             **2 (10.5%)**

Local Excision - complete excision with clear margins of less than 2cm or undefined margins; Wide or Radical Excision - complete excision with clear margins of 2 cm or more.

###### 

Details of disease recurrence and metastases of 19 case reports

  Recurrence/Metastases Outcome   *n* (%) (*n*=19)
  ------------------------------- ------------------
  No Recurrence                   5 (26.3%)
  Local Recurrence                6 (31.6%)
  Regional Recurrence             7 (36.8%)
  Distant Metastases              5 (26.3%)
  Not Reported                    4 (21.1%)

PCAC of the scalp is a rare malignancy most often reported in the literature as case reports or small case series.\[[@ref1]\] Approximately 200 cases were reported in the literature and most of those cases were originated in areas with large numbers of apocrine glands as the axilla. It is difficult to distinguish between PCAC and metastatic adenocarcinoma of the breast as both of them have the same morphological features. Limited work has been done analyzing the treatment options, prognosis, and outcomes available for the various stages of this malignancy. In our review, we were able to identify 19 cases of scalp primaries. At initial presentation, most cases had localized disease while regional lymph node metastases were less prevalent. Data suggests larger primaries at initial presentation may indicate the poor outcome, due to their tendency to metastasize; prognosis is often fatal upon the evidence of metastatic disease.\[[@ref1]\] Our data were consistent with previous demographic and prognostic findings from other PCAC primaries.\[[@ref1]\] A review of 186 cases was done by Brown *et al.*, analyzing several PCAC primaries, showed that similar to scalp lesions, patients most often present with localized disease, while metastases to the lymph nodes and distant regions is less common.\[[@ref1]\] For the treatment of localized PCAC, the current consensus tends to support the use of wide surgical resection. Due to insufficient data, surgical margins have not been standardized; however, 1--2 cm may provide sufficient eradication of tumor cells. According to the aggressive nature of larger scalp lesions exceeding 5 cm, some reports have suggested the use of adjuvant radiation in the treatment protocol to improve survival rates.\[[@ref16][@ref17]\] Based on the low risk of occult lymph node metastases, there is no need to do neck dissection in case of node-negative malignancy (N0). Neck dissection followed by adjuvant radiotherapy was offered to the patient presented with cervical lymph node metastasis. Hollowell\[[@ref4]\] recommended the use of sentinel lymph node biopsy (SLNB) to guide treatment planning, but due to the low incidence rate of PCAC, SLNB has not undergone prospective evaluation. Due to the low incidence rate of PCAC, individualized treatment should be addressed. Chemotherapy should be reserved for treating the advanced disease that often proves to be fatal and the initiation of palliative care in these circumstances is inevitable.\[[@ref3]\] The prognosis among scalp cases is limited due to such a small sample size; however, survival seems to correlate with data from various primaries. In our case, our patient remains disease-free at 24 months post-surgery. These results are consistent with previous case reports in the literature.

Relevance to the healthcare practice {#sec2-2}
------------------------------------

Primary apocrine carcinoma of the scalp is a rare malignancy. Following an in-depth review of the literature on the scalp PCAC, it can be concluded that the recommendation for wide surgical resection with cleared margins seems to be appropriate among patients with local, node-negative disease. One to two centimeters surgical margins are generally accepted standards. Patients with metastases regional lymph node have lower median survival rates and may benefit from neck dissection and additional radiation. The use of chemotherapy and radiation may also be considered in patients with the advanced and distant disease, as well as recurrence, as palliative but should be decided on a case-to-case basis.
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